These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 799568)

  • 1. Clinical and haemodynamic study of a new vasodilator drug L6150 (3-[bis-(2-hydroxyethyl)amino]-6-hydrazinopyridazine) in man.
    Brod J; Bahlmann J; Cachovan M; Dahlgrün H; Prexschner P; Futterová M
    Clin Sci Mol Med Suppl; 1976 Dec; 3():601s-603s. PubMed ID: 799568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacology of a new hypotensive drug with peripheral vasodilating action (ISF 2123); effects of acute intravenous administration in hypertensive patients].
    Terzoli L; Bianchini C; Cornelli U; Sala C; Leonetti G; Zanchetti A
    Boll Soc Ital Cardiol; 1977; 22(7):1053-6. PubMed ID: 618241
    [No Abstract]   [Full Text] [Related]  

  • 3. Oxdralazine, a new peripheral vasodilator, combined with propranolol and hydrochlorothiazide: a rational approach to antihypertensive treatment.
    Bartoli E; Faedda R; Arras S; Satta A; Soggia G
    J Clin Pharmacol; 1979; 19(11-12):751-7. PubMed ID: 536472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: a new beta blocker on the horizon.
    Katira R; Chauhan A
    Indian Heart J; 2000; 52(1):86-8. PubMed ID: 10820942
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound.
    Leonetti G; Terzoli L; Sala C; Bianchini C; Zanchetti A
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():461s-463s. PubMed ID: 6108817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.
    Agabiti-Rosei E; Alicandri CL; Beschi M; Castellano M; Fariello R; Montini E; Muiesan ML; Romanelli G; Muiesan G
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):87S-92S. PubMed ID: 7093104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vasculat for intravenous infusion. Tolerance and therapeutic effects].
    Curti PC; Patruno P; Bettini V; Camerota G
    Minerva Cardioangiol; 1973 Sep; 21(9):625-8. PubMed ID: 4147633
    [No Abstract]   [Full Text] [Related]  

  • 8. [Vasoactive combination treatment in cerebrovascular sclerosis].
    Klein K
    Wien Med Wochenschr; 1973 Jan; 123(1):14-8. PubMed ID: 4405190
    [No Abstract]   [Full Text] [Related]  

  • 9. Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.
    van Brummelen P; Bühler FR; Kiowski W; Bolli P; Bertel O
    Int J Clin Pharmacol Biopharm; 1979 Oct; 17(10):380-5. PubMed ID: 40887
    [No Abstract]   [Full Text] [Related]  

  • 10. Haemodynamic and endocrinological changes during anti-hypertensive treatment with a new vasodilator substance (L6150) and propranolol.
    Wester A; Zaal GA; de Leeuw PW; Birkenhäger WH
    Clin Sci Mol Med Suppl; 1976 Dec; 3():605s-607s. PubMed ID: 1071688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on agents with vasodilator and beta-blocking activities. I.
    Seki T; Takezaki T; Ohuchi R; Ohuyabu H; Ishimori T; Yasuda K
    Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1609-16. PubMed ID: 7954913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study.
    Kleber FX; Bollmann T; Borst MM; Costard-Jäckle A; Ewert R; Kivikko M; Petterson T; Pohjanjousi P; Sonntag S; Wikström G
    J Clin Pharmacol; 2009 Jan; 49(1):109-15. PubMed ID: 18981240
    [No Abstract]   [Full Text] [Related]  

  • 14. Nebivolol: a review.
    Cockcroft J
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150.
    Maseri A; Pesola A; L'Abbate A; Contini C; Magini G
    J Int Med Res; 1976; 4(6):402-9. PubMed ID: 1027634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of oxdralazine and dihydralazine in essential hypertension.
    Salvadeo A; Villa G; Segagni S; Piazza W; Criscuolo D
    Int J Clin Pharmacol Ther Toxicol; 1981 Aug; 19(8):372-6. PubMed ID: 7030978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antihypertensive pharmacotherapy with the vasodilators captopril and endralazine].
    Hartmann HG; Schumacher H
    Schweiz Med Wochenschr; 1985 Jul; 115(27-28):939-44. PubMed ID: 2862703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of dilated cardiomyopathy with intractable heart failure treated with adjunctive therapy of pimobendan and denopamine].
    Fujita T; Tsuda T; Nonaka R; Miyajima T; Tanaka Y; Kodama M; Izumi T; Shibata A
    Nihon Naika Gakkai Zasshi; 1992 Jul; 81(7):1108-10. PubMed ID: 1402256
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of 1-(4-oxyphenyl)-1-oxy-2-n-butylaminoethane sulfate on peripheral vascular diseases].
    Giulini SM; Agus GB; De Cristoforo A
    Minerva Cardioangiol; 1973 Jun; 21(6):434-8. PubMed ID: 4146376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.